ROCK1 and metabolic disease: In cardiovascular and metabolic diseases, isoform-specific targeting of ROCK1 or ROCK2 holds promise for improving endothelial function, attenuating fibrosis, and protecting against diabetic complications such as cardiomyopathy and nephropathy.